EGFR-IN-182
EGFR-IN-182 (Compound 4) is an EGFR inhibitor with an IC50 value of 199 nM. EGFR-IN-182 inhibits HSP90 and PI3K, with IC50 values of 5.007 and 13.596 μM respectively. EGFR-IN-182 exhibits strong anti-proliferative activity against MCF-7 and MDA-MB-231 cells. EGFR-IN-182 downregulates Cyclin D1, inducing cell cycle arrest; it enhances the activity of caspase-9, inducing cell apoptosis. EGFR-IN-182 downregulates the expressions of ERK and AKT. EGFR-IN-182 can be used for research on breast cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C25H18N8
- Masse moléculaire:430.46
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform EGFR
MoreVoir tous les produits spécifiques à Isoform Caspase
More
Activité biologique
|
EGFR 199 nM (IC50) |
HSP90 5.007 μM (IC50) |
PI3K 13.596 μM (IC50) |
Caspase 9 |
ERK |
Akt |
Chemical Information
-
Masse moléculaire 430.46
-
Formule C25H18N8
-
SMILES
N1(CC2=CC=CC=C2)C3=NC(N/N=C/C4=NC(C=CC=C5)=C5N=C4)=NN=C3C6=C1C=CC=C6
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
EGFR-IN-182 Related Classifications
HY-178955 Related Classifications
Powered by Bioz
- EGFR-IN-182
- EGFR
- HSP
- PI3K
- Caspase
- Apoptosis
- CDK
- ERK
- Akt
- Triazino[5,6-b]indole-hydrazones
- Triazino[5,6-b]indole-fused heterocyclic hybrids
- EGFR enzyme inhibition
- Hsp90 inhibition
- PI3K-AKT signaling
- ERK/AKT signaling
- Caspase-9 activation
- In silico docking study
- Cancer drug design
- Multi-target inhibitors in cancer therapy
- Inhibitor
- inhibitor
- inhibit